Genprex

News

Genprex Issues Shareholder Letter and Provides Corporate Update

Major milestones achieved in advancing gene therapies for lung cancer and diabetes

Read More

Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4

Company to provide update on upcoming clinical trials for the treatment of non-small cell lung cancer and an overview of its diabetes gene therapy

Read More

Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo

Presentation to Highlight Company’s Recent Advancements on its Upcoming Clinical Trials for the Treatment of Non-Small Cell Lung Cancer

Read More

Genprex to Present at NobleCon17 on January 19

Presentation to Highlight the Company’s Recent Progress on its Upcoming Clinical Trials for the Treatment of Non-Small Cell Lung Cancer

Read More

Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer

Company passes final release tests of scaled-up clinical grade production to supply drug product for upcoming Acclaim-1 and Acclaim-2 clinical trials in lung cancer

Read More

The Most Studied Research, Most Popular Videos, and Most Read Articles of 2020

What do small cap and micro cap investors look at? We thought you’d want to know what we discovered when we took a look back at Channelchek’s most popular content of 2020.

Read More

The Best (And Worst) Austin Stocks In 2020

And the winners are …

Genprex Inc. (Nasdaq: GNPX), a gene therapy company headquartered in the Texas capital, took the regional title of the year’s largest increase in share value.

Read More

Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants

Proceeds will add resources for the Company’s Acclaim-1 and Acclaim-2 clinical trials in lung cancer, as well as its pre-clinical programs in cancer and diabetes

Read More

Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants

Genprex has entered into a securities purchase agreement with a single healthcare-dedicated institutional investor for the purchase and sale of 3,116,884 shares of its common stock at a purchase price of $3.85 per share in a registered direct offering priced at-the-market under Nasdaq rules.

Read More

Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer

Major Manufacturing Milestone Positions the Company for Success In the Lung Cancer Therapeutics Market, Expected to Grow to $26.3 Billion by 2023

Read More